CAR T-Cell Therapy Sends Treatment-Resistant Rheumatoid Arthritis Into Remission in Phase 1 Trial

Three patients with rheumatoid arthritis that had beaten every drug their doctors tried are now off all arthritis medication, according to results from the world's first clinical trial of CAR T-cell therapy in this disease.

The phase 1 COMPARE trial, conducted at Charité-Universitätsmedizin Berlin and published August 27 in Nature Medicine, is a small but closely watched proof of concept. <cite index="13-4,13-5">The research team enrolled six patients with particularly severe disease, three women and three men aged 31 to 69, who had received up to eight targeted or biologic therapies over the previous ten years without adequate relief.</cite>

<cite index="12-1">CAR T-cell therapy dramatically reduced disease activity in all six, with three achieving medication-free remission.</cite> <cite index="13-8">During follow-up of up to one year, those three patients were in sustained remission without any medication for rheumatoid arthritis,</cite> according to Gerhard Krönke, who leads the Clinical Rheumatology research group at Charité and the German Rheumatology Research Center.

The therapy works by pulling T cells from a patient's own blood, genetically reprogramming them in a lab to seek out a surface protein called CD19 found on B cells, then infusing them back. <cite index="18-3,18-4,18-5">Rheumatoid arthritis begins when the immune system turns against the tissue lining the joints; the resulting inflammation causes pain, stiffness, and swelling, and available medications generally control it by continuously suppressing parts of the immune response rather than correcting the underlying malfunction.</cite> The CAR T approach is different in intent: it tries to clear the disease-driving B cells entirely.

<cite index="12-3">The treatment may work by clearing out harmful immune cells and effectively rebooting part of the immune system, although much larger studies are still needed.</cite>

One safety concern with wiping out B cells is that patients could lose immune memory built up from prior vaccinations. The Berlin team looked at that closely. <cite index="13-9,13-10">Protective antibodies from previous vaccinations, for example against chickenpox or tetanus, remained detectable, and despite the profound depletion of B cells, protective antibody memory appears to be largely preserved.</cite> That's a meaningful finding for patients and clinicians alike, though the team was careful to note that longer-term effects on the immune system are still unknown.

Responses weren't uniform. <cite index="17-11,17-12">CAR T-cell therapy for autoimmune diseases, and for rheumatoid arthritis in particular, remains experimental, and there isn't yet any long-term experience with this treatment.</cite> Three of the six patients reached remission; the other three did not, and the trial wasn't designed to explain why.

<cite index="14-3">The COMPARE trial evaluated mivocabtagene autoleucel, an autologous fully human CD19-directed CAR T-cell therapy, in patients with anti-citrullinated protein antibody-positive, treatment-refractory active rheumatoid arthritis.</cite> That's a specific, well-defined population, and it matters: the patients in this trial weren't people whose first or second drug stopped working. They had cycled through up to eight advanced therapies over a decade.

<cite index="16-1,16-2">A phase 2 COMPARE trial will enroll ten additional patients and compare mivocabtagene autoleucel directly against an approved B-cell-targeting drug, with enrollment expected to begin before the end of 2026.</cite>

For rheumatologists, the question isn't whether a cancer-derived cell therapy can knock down inflammation in this population. The trial answers that, at least provisionally. <cite index="16-4">The question the field is now watching is not whether CAR T can clear treatment-resistant arthritis, but how long the reset lasts.</cite>

For patients, the framing is simpler and harder. CAR T-cell therapy currently requires a hospital stay, carries real risks, and isn't approved for any autoimmune indication. But for someone who's been in pain for a decade and has run out of approved options, a single infusion that might buy years off medication is the kind of result worth following into phase 2.

Sources cited:
- Nature Medicine (via EurekAlert) (https://www.eurekalert.org/news-releases/1141735)
- ScienceDaily (https://www.sciencedaily.com/releases/2026/08/260828082330.htm)
- MedicalXpress (https://medicalxpress.com/news/2026-08-cell-therapy-substantially-severe-rheumatoid.html)
- Hospital Healthcare Europe (https://hospitalhealthcare.com/specialisms/rheumatology/car-t-therapies-in-refractory-rheumatic-and-msk-diseases-a-view-from-eular-2026/)
- Martin Cid Magazine (https://www.martincid.com/science/car-t-rheumatoid-arthritis-remission-nature-medicine-2026/)